Company news

Scholar Rock Holding Corporation news in 2025

Scholar Rock Holding Corporation's news releases, calls and decks from 2025, newest first.

View company

Scholar Rock to Present at Upcoming Investor Conferences

November 17, 2025

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 13, 2025

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

November 3, 2025

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

October 22, 2025

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

September 22, 2025

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

August 13, 2025

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

August 6, 2025

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

July 20, 2025

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

June 22, 2025

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

June 17, 2025

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

June 4, 2025

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

June 1, 2025

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 27, 2025

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 13, 2025

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

May 6, 2025

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

April 27, 2025

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

March 24, 2025

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

March 15, 2025

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

February 26, 2025

Scholar Rock to Participate in Upcoming Investor Conferences

February 24, 2025

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

February 20, 2025

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

February 9, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

January 28, 2025

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

January 28, 2025

Scholar Rock Highlights 2025 Strategic Priorities

January 7, 2025

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Calls in 2025

Decks in 2025